AIMS/HYPOTHESIS: To examine the prevalence and associations with the metabolic syndrome of albuminuria among Australian Aboriginal people. METHODS: Early-morning urine specimens were collected as part of community-based risk factor surveys assessing the prevalence of diabetes and cardiovascular disease in eight remote communities, with a sample size of 1,075 people. Microalbuminuria was defined as urinary albumin : creatinine ratio 3.4-33.9 mg/mmol, macroalbuminuria as albumin: creatinine ratio equal to or greater than 34 mg/mmol. RESULTS: There were high prevalences of microalbuminuria (men 22.2 %, women 26.9 %) and of macroalbuminuria (men 10.4%, women 13.5%). There were highly statistically significant linear associations of microalbuminuria and macroalbuminuria with increasing number of coexisting components of the metabolic syndrome (hypertension, glucose intolerance, dyslipidaemia, insulin resistance, abdominal obesity): among people with zero, one, two and three to five of these conditions, respectively, prevalence of microalbuminuria was 16%, 20%, 36% and 32% (p < 0.001); prevalence of macroalbuminuria was 2%, 6%, 12% and 32% (p < 0.001). There were independent associations of microalbuminuria with hypertension (odds ratio, 95% confidence interval = 2.36, 1.63-3.42) and diabetes (2.10, 1.28-3.45): macroalbuminuria was independently associated with hypertension (6.39, 3.93-10.4), diabetes (3.49, 1.93-6.28) and abdominal obesity (4.56, 2.40-8.64) and had a weaker association with insulin resistance (1.99, 1.12-3.54). Dyslipidaemia and impaired glucose tolerance were neither independently associated with microalbuminuria or macroalbuminuria, nor was insulin resistance or abdominal obesity independently associated with microalbuminuria. CONCLUSION/ INTERPRETATION: There was a strong clustering of albuminuria with components of the metabolic syndrome. Diabetes, hypertension and abdominal obesity are major contributors to high rates of albuminuria among Australian Aboriginal people.
AIMS/HYPOTHESIS: To examine the prevalence and associations with the metabolic syndrome of albuminuria among Australian Aboriginal people. METHODS: Early-morning urine specimens were collected as part of community-based risk factor surveys assessing the prevalence of diabetes and cardiovascular disease in eight remote communities, with a sample size of 1,075 people. Microalbuminuria was defined as urinary albumin : creatinine ratio 3.4-33.9 mg/mmol, macroalbuminuria as albumin: creatinine ratio equal to or greater than 34 mg/mmol. RESULTS: There were high prevalences of microalbuminuria (men 22.2 %, women 26.9 %) and of macroalbuminuria (men 10.4%, women 13.5%). There were highly statistically significant linear associations of microalbuminuria and macroalbuminuria with increasing number of coexisting components of the metabolic syndrome (hypertension, glucose intolerance, dyslipidaemia, insulin resistance, abdominal obesity): among people with zero, one, two and three to five of these conditions, respectively, prevalence of microalbuminuria was 16%, 20%, 36% and 32% (p < 0.001); prevalence of macroalbuminuria was 2%, 6%, 12% and 32% (p < 0.001). There were independent associations of microalbuminuria with hypertension (odds ratio, 95% confidence interval = 2.36, 1.63-3.42) and diabetes (2.10, 1.28-3.45): macroalbuminuria was independently associated with hypertension (6.39, 3.93-10.4), diabetes (3.49, 1.93-6.28) and abdominal obesity (4.56, 2.40-8.64) and had a weaker association with insulin resistance (1.99, 1.12-3.54). Dyslipidaemia and impaired glucose tolerance were neither independently associated with microalbuminuria or macroalbuminuria, nor was insulin resistance or abdominal obesity independently associated with microalbuminuria. CONCLUSION/ INTERPRETATION: There was a strong clustering of albuminuria with components of the metabolic syndrome. Diabetes, hypertension and abdominal obesity are major contributors to high rates of albuminuria among Australian Aboriginal people.
Authors: Jean W MacCluer; Marina Scavini; Vallabh O Shah; Shelley A Cole; Sandra L Laston; V Saroja Voruganti; Susan S Paine; Alfred J Eaton; Anthony G Comuzzie; Francesca Tentori; Dorothy R Pathak; Arlene Bobelu; Jeanette Bobelu; Donica Ghahate; Mildred Waikaniwa; Philip G Zager Journal: Am J Kidney Dis Date: 2010-06-19 Impact factor: 8.860
Authors: Erin Rademacher; Michael Mauer; David R Jacobs; Blanche Chavers; Julia Steinke; Alan Sinaiko Journal: Clin J Am Soc Nephrol Date: 2008-04-09 Impact factor: 8.237
Authors: Louise J Maple-Brown; Joan Cunningham; Allison M Hodge; Tarun Weeramanthri; Terry Dunbar; Paul D Lawton; Paul Z Zimmet; Steve J Chadban; Kevan R Polkinghorne; Jonathan E Shaw; Kerin O'Dea Journal: BMC Public Health Date: 2011-05-19 Impact factor: 3.295
Authors: David Ross Johnson; Robyn Anne McDermott; Peter Marshall Clifton; Katina D'Onise; Sean Matthew Taylor; Cilla Louise Preece; Barbara Anne Schmidt Journal: BMC Public Health Date: 2015-04-03 Impact factor: 3.295
Authors: Julie Brimblecombe; Megan Ferguson; Selma C Liberato; Kylie Ball; Marjory L Moodie; Anne Magnus; Edward Miles; Amanda J Leach; Mark D Chatfield; Cliona Ni Mhurchu; Kerin O'Dea; Ross S Bailie Journal: BMC Public Health Date: 2013-08-12 Impact factor: 3.295
Authors: Amy K Mottl; Abigail Lauer; Dana Dabelea; David M Maahs; Ralph B D'Agostino; Larry M Dolan; Lisa K Gilliam; Jean M Lawrence; Beatriz Rodriguez; Santica M Marcovina; Giuseppina Imperatore; Roopa Kanakatti Shankar; Maryam Afkarian; Kristi Reynolds; Angela D Liese; Michael Mauer; Elizabeth J Mayer-Davis Journal: Diabetes Care Date: 2013-07-11 Impact factor: 19.112